Norris Trophy winner Zach Werenski (@BlueJacketsNHL) moves up six spots on NHL Network's Top 50 Players Right Now list!
📺: #NHLTopPlayers# on NHL Network
Novo Nordisk will pay as much as $2.6 billion to license an experimental obesity pill from China’s Hengrui, as it seeks to rebuild investor confidence in its future beyond blockbusters Ozempic and Wegovy
Novo Nordisk signed a deal worth as much as €1.165 billion with Sweden’s Nanexa for rights to its drug delivery technology for obesity and diabetes treatments
Novo Nordisk — the company behind Ozempic — is eyeing the hair-loss market.
CEO Mike Doustdar said building on the company's expertise in selling drugs directly to consumers was an opportunity "to win"
📷️: Jose Sarmento Matos/Bloomberg